Distinct mouse models of Stargardt disease display differences in pharmacological targeting of ceramides and inflammatory responses
Open Access
- 8 December 2023
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (50)
Abstract
Mutations in many visual cycle enzymes in photoreceptors and retinal pigment epithelium (RPE) cells can lead to the chronic accumulation of toxic retinoid byproducts, which poison photoreceptors and the underlying RPE if left unchecked. Without a functional ATP-binding cassette, sub-family A, member 4 (ABCA4), there is an elevation of all- trans -retinal and prolonged buildup of all- trans -retinal adducts, resulting in a retinal degenerative disease known as Stargardt-1 disease. Even in this monogenic disorder, there is significant heterogeneity in the time to onset of symptoms among patients. Using a combination of molecular techniques, we studied Abca4 knockout (simulating human noncoding disease variants) and Abca4 knock-in mice (simulating human misfolded, catalytically inactive protein variants), which serve as models for Stargardt-1 disease. We compared the two strains to ascertain whether they exhibit differential responses to agents that affect cytokine signaling and/or ceramide metabolism, as alterations in either of these pathways can exacerbate retinal degenerative phenotypes. We found different degrees of responsiveness to maraviroc, a known immunomodulatory CCR5 antagonist, and to the ceramide-lowering agent AdipoRon, an agonist of the ADIPOR1 and ADIPOR2 receptors. The two strains also display different degrees of transcriptional deviation from matched WT controls. Our phenotypic comparison of the two distinct Abca4 mutant-mouse models sheds light on potential therapeutic avenues previously unexplored in the treatment of Stargardt disease and provides a surrogate assay for assessing the effectiveness for genome editing.Keywords
Funding Information
- HHS | NIH | National Eye Institute (EY009339)
- HHS | NIH | National Eye Institute (1F31EY034027-01)
- HHS | NIH | National Eye Institute (EY034070)
- Knights Templar Eye Foundation (2023-17)
- The International Centre for Translational Eye Research (MAB/2019/12)
- the International Research Agendas program of the Foundation for Polish Science co-financed by the European Union under the European Regional Development Fund (no number)
- Polish National Science Centre project (2019/34/E/NZ5/00434)
This publication has 78 references indexed in Scilit:
- CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon ResponseImmunity, 2013
- Mechanism of All-trans-retinal Toxicity with Implications for Stargardt Disease and Age-related Macular DegenerationJournal of Biological Chemistry, 2012
- Gain-of-Function Mutations of ARHGAP31, a Cdc42/Rac1 GTPase Regulator, Cause Syndromic Cutis Aplasia and Limb AnomaliesThe American Journal of Human Genetics, 2011
- Noninvasive multiphoton fluorescence microscopy resolves retinol and retinal condensation products in mouse eyesNature Medicine, 2010
- Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosaProceedings of the National Academy of Sciences, 2010
- Mutations in IMPG2, Encoding Interphotoreceptor Matrix Proteoglycan 2, Cause Autosomal-Recessive Retinitis PigmentosaThe American Journal of Human Genetics, 2010
- Identification of Genes and Pathways Involved in Retinal Neovascularization by Microarray Analysis of Two Animal Models of Retinal AngiogenesisInvestigative Ophthalmology & Visual Science, 2010
- The role of the photoreceptor ABC transporter ABCA4 in lipid transport and Stargardt macular degenerationBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- ABCA4 disease progression and a proposed strategy for gene therapyHuman Molecular Genetics, 2008
- Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapyGene Therapy, 2008